



EFFICIENT SYNTHESIS OF 1,2-*seco* AND 1,2-*seco* 2-*nor*
PYRIMIDINE AND PURINE NUCLEOSIDES.

Muhammad AZYMAH, Claude CHAVIS, Marc LUCAS and Jean-Louis IMBACH*

Laboratoire de Chimie Bio-Organique, associé au CNRS, Université
de Montpellier II, 34060 Montpellier-Cédex 1, France.

Unprotected silylated purines and pyrimidines (adenine, guanine, cytosine, thymine) reacted with acetoxymethyl ether (acyclic sugar analogues) under solid PTC conditions, using KI and dibenzo-18-crown-6 in benzene-acetonitrile (1:1, v/v) to give regiospecifically the corresponding N-9 purine and N-1 pyrimidine acyclic nucleosides in fairly good yields.


Since the discovery of Acyclovir 1 [9-(2-hydroxyethoxy)-methyl]guanine as a selective antiherpes agent¹, attention has focused to the synthesis and antiviral evaluation of an increasing number of acyclic nucleoside analogues^{2,3}; one of the most potent compounds synthesized to date is DHPG 2 ([9-(1,3-dihydroxy-2-propoxy)methyl] guanine⁴.



Altered nucleosides bearing acyclic variations in the sugar moiety were synthesized either from natural nucleosides⁵ (i.e. 2,3-*seco* nucleosides) or by reaction between the appropriate pseudo-sugar moiety and the purine or pyrimidine ring. To date, these latter procedures applied to the synthesis of acyclic nucleosides of the general formula R-O-CH₂-B (B=N-9 purinyl or N-1 pyrimidinyl) started from halomethyl ethers R-O-CH₂X (X = Br, Cl) which were reacted with silylated nucleobases with or without^{6,7} catalyst (Friedel-Crafts⁸, p.toluene sulfonic acid⁴, triethylamine^{9,10}, mercuric cyanide^{11,12}, nBu₄N¹²⁻¹⁶, ZnI₂¹⁷, CsI¹⁸, (CH₃)₃SiI^{19,20}, TDA²¹). Whenever it

was possible, condensation occurred between the sodium salt of the base and halomethyl ether²². Finally, transpurination reaction had been applied to the synthesis of acyclonucleosides²³.

Most of these reactions described in the literature exhibit low regioselectivity and their yields are generally unsatisfactory. As we are interested in the synthesis of chiral acyclic nucleosides, we devised a simple and general method which affords high yields of the natural N-9 purine and N-1 pyrimidine derivatives as exemplified in scheme 1. In this way the readily available protected acetoxymethyl ether of glycerol 3¹⁰ and homochiral (2S,3S) L-threitol 4²⁴ were reacted with silylated nucleobases (a,b,c,d) (1 mmol) in refluxing acetonitrile-benzene mixture (1:1, v/v, 10 ml) under phase transfer conditions using dibenzo-18-crown-6 (0.2 mmol) and potassium iodide (0.8 mmol). After filtration, the solution was evaporated under reduced pressure. The residue was subjected to a short column chromatography in order to eliminate the coronand from the desired compounds 5 and 6. As reported in scheme 1, N-9 purinyl and N-1 pyrimidinyl acyclic nucleosides were obtained as the sole products in fairly good yields. Removal of the benzoyl groups by methanolic ammonia gave the compounds 7 and 8 in quantitative yields.



Scheme 1

The unprotected acyclic nucleosides 7 derived from glycerol were fully characterised^{25,31} and their analytical data were in accordance with the literature.

Among the 1,3S,4-trihydroxy-2S-butoxymethyl nucleosides 8a-8d, two (i.e. 8a and 8c) were prepared^{14,28,29} in an overall yield not exceeding 30%. It is worth mentioning that in the case of the guanine derivative 8c, an equal amount of N-9 and N-7 isomers were obtained^{29,14} and had to be separated. Analytical data^{30,31} for all compounds 6a-6d and 8a-8d reported

in this communication were consistent with the structures given.

This process constitutes a simple and highly useful methodology for the regiospecific synthesis of acyclic nucleosides. Moreover, it has three advantages: - The exocyclic amino groups of nucleobases (Ad, Cy, Gu) need no further protection. - An acetoxymethyl ether can be used directly avoiding the preparation of the corresponding halomethyl ether. - High coupling yields are obtained. This approach opens the way to an easy regiospecific synthesis of various other series of acyclonucleosides.

REFERENCES AND FOOTNOTES

1. H.J. Schaeffer, L. Beauchamp, P. de Miranda, G. Elion, D-G. Bauer and P. Collins, *Nature (London)*, 1978, 272, 583.
2. R.J. Remy and J.A. Secrist III, *Nucleosides, Nucleotides*, 1985, 4, 411.
3. C.K. Chu and S.J. Cutler, *J. Heterocycl. Chem.*, 1986, 23, 289.
4. J.C. Martin, C.A. Dvorak, D.F. Smee, T.R. Matthews and J.P.H. Verheyden, *J. Med. Chem.*, 1983, 26, 759.
5. G. Beaton, A.S. Jones and R.T. Walker *Tetrahedron*, 1988, 44, 6419.
6. S.V. Kotchetkova, A.A. Khorlin, I.P. Smirnov, I.L. Tschaveleva, T.L. Tsilevich, B.R. Gottikii and V.L. Florentiev *Bioorg. Khim.*, 1989, 15, 133.
7. W.T. Ashton, L.F. Canning, G.F. Reynolds, R.C. Tolmann, J.D. Karkas, R. Liou, M.E.M. Davies, C.M. Dewitt, H.C. Perry and K. Field, *J. Med. Chem.*, 1985, 28, 916.
8. A. Rosowsky, S.H. Kim and M. Wick, *J. Med. Chem.*, 1981, 24, 1177.
9. K.K. Ogilvie and M.F. Gillen, *Tetrahedron Lett.*, 1980, 21, 327.
10. L.M. Beauchamp, L. Sterling, J.E. Kelsey, K.K. Biron, P. Collins, J. Selway, J.C. Lin and H.J. Schaeffer, *J. Med. Chem.*, 1988, 31, 144.
11. K.K. Ogilvie, R.G. Hamilton, M.F. Gillen and G.K. Radatus, *Can. J. Chem.*, 1984, 62, 16.
12. P. Vemishetti, E. Abushanab, R.W. Leiby and R.P. Panzica, *Nucleosides, Nucleotides*, 1989, 8, 201.
13. T. Ogawa, H. Takaku and N. Yamamoto, *Nucleosides, Nucleotides*, 1989, 8, 499.
14. G.H. Hakimelahi, M. Zarrineshad, A.A. Jarrahpour and H. Shargui, *Helv. Chim. Acta*, 1987, 70, 219.
15. E. Abushanab and M.P. Sarma, *J. Med. Chem.*, 1989, 32, 76.
16. H.B. Lazrek, M.L. Taha, J.L. Barascut and J.L. Imbach, *Nucleosides, Nucleotides*, 1987, 6, 379.
17. Y.H. Kim and J.Y. Kim, *Heterocycles*, 1988, 27, 71.
18. Y.H. Kim, J.Y. Kim and C.H. Lee, *Chem. Lett.*, 1988, 1045.
19. A. Matsuda, Y. Kurasawa and K.A. Watanabe, *Synthesis*, 1981, 748.

20. Z. Tocik, R.A. Earl and J. Benarek, *Nucleic Acids Res.*, 1980, **8**, 4755.
21. H. Rosemeyer and F. Seela, *Helv. Chim. Acta*, 1988, **71**, 1573.
22. J.S. Pudlo, N.K. Saxena, M.R. Nassiri, S.R. Turk, J.C. Drach and L.B. Townsend, *J. Med. Chem.*, 1988, **31**, 2086.
23. J. Boryski and B. Golankiewicz, *Nucleosides, Nucleotides*, 1989, **8**, 529.
24. This compound and its enantiomer were easily synthesized in five steps from L and D-tartaric acid dimethyl esters respectively. Their synthesis will be published in the forthcoming full paper.
25. **7a**: mp 182-183° (lit⁹ mp 184-186°) λ_{\max} (EtOH) 260; **7b**: mp 141-142° (lit²⁵ mp 141-142°) λ_{\max} (EtOH) 269; **7c**: mp > 300°dec. (lit^{4,27} mp > 285°dec.) λ_{\max} (EtOH)255; **7d**: mp 155-156° (lit⁹ mp 155-156°) λ_{\max} (EtOH) 264.
26. J.C. Martin, G.A. Jeffrey, D.P. Mc Gee, M.A. Tippie, D.F. Smee, T.R. Matthews and J.R. Verheyden, *J. Med. Chem.*, 1985, **28**, 358.
27. K.K. Ogilvie, U.O. Cheriyan, B.K. Radatus, K.O. Smith, K.S. Galloway and W.L. Kennel, *Can. J. Chem.*, 1982, **60**, 3005.
28. M. MacCoss, R.L. Tolman, W.T. Ashton, A.F. Wagner, J. Hannah, A.K. Field, J.D. Karkas and J.I. Germershausen, *Chemica Scripta*, 1986, **26**, 113.
29. M. MacCoss, A. Chen and R.L. Tolman, *Tetrahedron Lett.*, 1985, **26**, 4287.
30. ¹H-NMR (300 MHz, CDCl₃) ppm from TMS: **6a**: 8.2 (s, H₈), 7.36-7.93 (m, H₂, aromatics), 6.72 (br s, NH₂), 5.80 (ABq, NCH₂O), 5.64 (q, H₃'), 4.46-4.69 (m, H₄'₄"', H₁'₁"', H₂'). **6b**: 7.19-7.96 (m, NH₂, H₆, aromatics), 5.74 (d, H₅, J=7.35Hz), 5.67 (m, H₃'), 5.41 (d, NCHO, J=10.58Hz), 5.19 (d, NCHO), 4.41-4.65 (m, H₄'₄"', H₁'₁"', H₂'). **6c**: (DMSO-*d*₆): 10.84 (s, NH), 8.17 (s, H₈), 7.45-7.88 (m, aromatics), 6.22 (s, NH₂), 5.80 (s, NCH₂O), 5.64 (m, H₃'), 4.39-4.67 (m, H₄'₄"', H₁'₁"', H₂'). **6d**: 7.39-8.13 (m, NH, aromatics), 7.03 (d, H₆, J=1.28Hz), 5.72 (q, H₃'), 5.43 (d, NCHO, J=10.91Hz), 5.20 (d, NCHO), 4.53-4.76 (m, H₄'₄"', H₁'₁"', H₂'), 1.67 (d, CH₃, J=1.28Hz).
31. **8a**: mp 200° (lit¹⁴ mp 205°) λ_{\max} (EtOH) 260; **8b**: foam, λ_{\max} (EtOH) 269; **8c**: mp 295°dec. (lit²⁹ no data) λ_{\max} (EtOH) 253; **8d**: mp 112-113° λ_{\max} (EtOH) 264.

(Received in France 27 July 1989)